VANCOUVER, Oct. 4 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced results from a prospective, randomized, controlled, blinded clinical trial of its Periowave(TM) Photodynamic Disinfection (PDD) System for the treatment of periodontal diseases. Results showed significant improvement in pocket depth, clinical attachment level and bleeding on probing when compared to the gold standard of scaling and root planing (SRP).
